Selexipag
Platelet Aggregation Inhibitors Excl. Heparin
Sold as UPTRAVI
- Drug class
- Platelet Aggregation Inhibitors Excl. Heparin
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 18
Overview
Selexipag is an active pharmaceutical ingredient in the Platelet Aggregation Inhibitors Excl. Heparin group (B01AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 9 | May 22, 2026 |
| CA Canada | Health Canada | 8 | March 22, 2025 |
| EU European Union | EMA | 1 | February 19, 2026 |
GBUnited Kingdom· MHRA
9 products
Uses
Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.
1).
How to take
CACanada· Health Canada
8 products
Uses
UPTRAVI® (selexipag) is indicated for: the long-term treatment of idiopathic pulmonary arterial hypertension (iPAH), heritable pulmonary arterial hypertension (HPAH), PAH associated with connective tissue disorders and PAH associated with congenital heart disease, in adult patients with WHO fun ctional class (FC) II–III to delay disease progression.
2 Pharmacodynamics). UPTRAVI® is effective in combination with an endothelin receptor antagonist (ERA) or a phosphodiesterase-5 (PDE-5) inhibitor, or in triple combination with an ERA and a PDE-5 inhibitor, or as monotherapy. 1 Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of UPTRAVI® in children aged 0 to less than 18 years have not yet been established.
3 Pediatrics). 2 Geriatrics Geriatrics (≥ 65 years of age): Of the total number of subjects in the clinical study of UPTRAVI® for pulmonary arterial hypertension, 18% were 65 years of age and older. 4 Geriatrics).
EUEuropean Union· EMA
1 product
Uses
Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.
1).
How to take
Drug interactions
Known interactions involving Selexipag. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB002420759 · revised May 22, 2026
- [2]Health Canada (DPD) · 02451158 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/003774 · revised February 19, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.